

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2002 (27.12.2002)

PCT

(10) International Publication Number
WO 02/102362 A1

- (51) International Patent Classification⁷: **A61K 31/19, 35/78, A61P 3/04, 3/08**
- (21) International Application Number: **PCT/NL02/00394**
- (22) International Filing Date: **14 June 2002 (14.06.2002)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
09/880,937 15 June 2001 (15.06.2001) US
- (71) Applicant (*for all designated States except US*): **NUMICO RESEARCH B.V. [NL/NL]; P.O. Box 1, NL-2700 MA Zoetermeer (NL).**
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **VAN LAERE, Katrien, Maria, Jozefa [BE/NL]; Kamperfoeliestraat 11, NL-6666 WS Heteren (NL). RAGGERS, Rene, John [NL/NL]; Staalmeesterslaan 243, NL-1057 NX Amsterdam (NL).**
- (74) Agent: **JORRITSMA, Ruurd; Nederlandsch Octrooibureau, Scheveningseweg 82, P.O. Box 29720, NL-2502 LS THE HAGUE (NL).**
- (81) Designated States (*national*): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.**
- (84) Designated States (*regional*): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**
- Published:**
- *with international search report*
 - *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **DIETETIC PREPARATION AND USE OF AN ALPHA-HYDROXY CARBOXYLIC ACID (CITRIC ACID FOR THE TREATMENT OF OBESITY)**

(57) Abstract: This invention relates to a method of inhibiting intestinal carbohydrate absorption in mammals and a dietetic preparation for use in such a method. More particularly the present invention is concerned with a method of inhibiting intestinal absorption of carbohydrates in a mammal, which method comprises orally administering a dietetic preparation to such mammal, said preparation containing α -hydroxy carboxylic acid component, whose intestinal absorption is sodium dependent, in an amount equivalent to at least 1 wt.% citric acid, so as to provide α -hydroxy carboxylic acid component in an amount which is therapeutically effective to achieve inhibition of intestinal absorption of carbohydrate. Citric acid is an example of an α -hydroxy carboxylic acid which may suitably employed. The invention also encompasses a dietetic preparation in the form of an oral dosage unit of between 0.1 and 100 grams, said preparation containing between 2 and 90 wt.% of α -hydroxy carboxylic acid component whose intestinal absorption is sodium dependent, between 1 and 80 wt.% of a carbohydrate absorption inhibitor selected from the group consisting of polyphenols, gymnemic acid and mixtures thereof and between 97 and 99 wt.% of pharmaceutically acceptable excipient.

WO 02/102362 A1

DIETETIC PREPARATION AND USE OF AN ALPHA-HYDROXY CARBOXYLIC ACID (CITRIC ACID)
FOR THE TREATMENT OF OBESITY

Technical field

- 5 This invention relates to a method of inhibiting intestinal carbohydrate absorption in mammals and a dietetic preparation for use in such a method. More particularly the present invention is concerned with the administration of α -hydroxy carboxylic acid component, whose intestinal absorption is sodium dependent, in an amount effective to
- 10 achieve inhibition of intestinal carbohydrate absorption. The α -hydroxy carboxylic acids used in accordance with the invention can be represented by the general formula $R-C(OH)COOH-R$. Citric acid is an example of an α -hydroxy carboxylic acid which may suitably be employed in the present method.
- 15 The present invention also concerns a dietetic preparation in the form of an oral dosage unit of between 0.1 and 100 grams, said preparation containing between 2 and 90 wt.% of α -hydroxy carboxylic acid component, whose intestinal absorption is sodium dependent, between 1 and 80 wt.% of a carbohydrate absorption inhibitor selected from the group consisting of polyphenols, gymnemic acid and mixtures thereof, and pharmaceutically
- 20 acceptable excipient.

Background of the invention

- 25 Reduction of carbohydrate absorption in the intestine of animals, especially humans, is nutritionally and medically of great importance. Reduction of absorption can for example facilitate body weight management, e.g. as part of a method of treating obesity, and can be advantageous for subjects suffering from diabetes or hypoglycaemic state.
- 30 Reduced carbohydrate absorption by the intestine is thought to reduce fat formation. In a normal diet many carbohydrate containing components are present. During digestion of

the carbohydrates, monosaccharides, e.g. glucose, will be formed which can be readily absorbed by the intestine. The absorbed glucose can subsequently be converted to water and carbon dioxide, glycogen, glycol or fatty acids, the last predominantly occurring when an excess of glucose is present, e.g. when a vast amount of carbohydrates is consumed.

Many preparations have been proposed to reduce carbohydrate digestion either alone or in combination with components capable of reducing absorption of the carbohydrates in the intestine. Such compositions will ultimately result in the reduced *in vivo* availability of glucose, thereby reducing the formation of adipose tissue, contributing to weight loss, reducing blood glucose levels, decreasing fluctuations in blood glucose levels etc. These effects are advantageous for e.g. obese or diabetic subjects and subjects having the desire to maintain a low weight or desirable silhouette.

Reduction of carbohydrate digestion can for example be accomplished by the ingestion of components capable of reducing digestive enzyme activity, e.g. by reducing pancreatic amylase and α -glucosidase activity.

α -Glucosidase converts non-absorbable dietary starch and sucrose into absorbable monosaccharides. Inhibitors of α -glucosidase inhibit such conversion, resulting in the delay of formation and absorption of monosaccharides. Therefore, these inhibitors reduce the concentration of post-prandial blood glucose.

An amylase inhibitor reduces the activity of human pancreatic α -amylase and moderates the digestion of ingested starch by inhibiting the conversion of carbohydrates into smaller carbohydrate polymers, thus inhibiting an increase in blood glucose level and reducing insulin secretion.

US5840705 discloses an α -glucosidase inhibitor mildly inhibiting α -glucosidase locally present in the micro-villus of the small intestine. The inhibitor delays the digestion of starch, starch-derived oligosaccharides and sucrose, so that the inhibitor has an action of suppressing rapid increase in blood glucose level and an action of suppressing insulin secretion at a lower level.

US6174904 discloses a method for treating glycometabolism disorders in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of an insulin sensitivity enhancer in combination with an α -glucosidase inhibitor, wherein said α -glucosidase inhibitor can be acarbose, voglibose and miglitol, and the insuline sensitivity enhancer can be troglitazone.

JP2000103742 discloses an α -amylase inhibitor obtained from extracts of Gambir, a material obtained from the root of *Sassafras albidum*, having high safety and capable of suppressing absorption of carbohydrates and preventing obesity, diabetes, or the like.

Reduction of absorption of glucose in the intestine can for example be accomplished by intestinal absorption reducing components such as gymnemic acid, which can be extracted from *Gymnema sylvestre* as reported by Shimizu et al. "Suppression of glucose absorption by some fractions extracted from *Gymnema sylvestre* leaves", J. Vet Med. Sci (1997), 59(4), 245-251.

Combinations of components capable of reducing the activity of intestinal carbohydrate degrading enzymes and components which reduce the intestinal absorption of glucose are for example described in WO0117369, which discloses the combination of α -amylase inhibitors, for example plant protein derived α -amylase inhibitors and absorption inhibitors e.g. inulin and fructo-oligosaccharides.

Although many of the compositions reducing carbohydrate absorption are know in the art and available on the market, still such compositions are open to improvements, particularly because of undesirable side effects occurring when administering these compositions in substantial amounts. Commercially available compositions that include effective enzyme inhibitors and/or components which reduce intestinal glucose absorption are found to cause insufficient water uptake, potentially resulting in dehydration. Glucose is co-transported over the intestinal wall with salt, and thus fulfils the important role of increasing the cellular concentration of salt within the intestine and

inducing osmotic water transport from the intestine to the cells. Reduced glucose transport, e.g. due to reduced availability of glucose or inhibition of carbohydrase enzymes, will result in reduced water transport. The resulting reduction in water absorption is a common and undesirable side effect of existing compositions comprising
5 carbohydrase inhibiting components and/or glucose absorption inhibiting components. The decreased water uptake observed for these compositions often leads to increased excretion of water in the faeces, a cause of diarrhea and other adverse effects. Thus the need for a potent and safe amylase inhibitor and/or glucosidase inhibitor which can suitably be used in compositions which reduce glucose absorption in the intestine is well
10 recognised in the art.

Another drawback of many compositions currently available suitable for the purposes indicated above, is the inclusion therein of components of which no extensive safety data exist, making the use, especially long term use of such products dubious and potentially
15 unsafe.

Summary of the invention

20 Surprisingly, it was found that the administration of an effective amount of α -hydroxy carboxylic acid component, whose intestinal absorption is sodium dependent, provides a solution to the above problems. The use of such α -hydroxy carboxylic acid components fulfils a long standing need for a safe and effective method of inhibiting carbohydrate absorption, without the risks of diarrhoea and dehydration that are associated with the use
25 of existing carbohydrase inhibitors. An example of an α -hydroxy carboxylic acid that may advantageously be used in accordance with the present invention is citric acid. Citric acid is used in many applications, particularly in the food industry. However, the use of citric acid in a method of inhibiting intestinal carbohydrate absorption is not disclosed in
30 the prior art.

US 4,689,219 describes oral pharmaceutical compositions in dry powder or granular form adapted to be added to water or a drink for treatment of diabetes, which compositions comprise xanthan gum and locust bean gum as well as 2.5 to 10 wt.% of an organic acid such as citric acid. The combination of xanthan gum and locust bean gum is said to have an inhibitory effect on the diffusion of glucose across a membrane. The organic acid is included to control the rate of gelation of the mixture of the 2 aforementioned gums.

A nutritional tea beverage currently on the market under the name "Herbal Slimmer" from Tribal Tonics™ comprises green tea extract, other herbal extracts and citric acid. The product has a high content of carbohydrates. Another nutritional beverage product "Over 30™" also contains green tea and citric acid and a vast amount of digestible carbohydrates.

Hansawasdi et al, "α- Amylase Inhibitors from Roselle Tea", Biosc. Biotechnol. Biochem. (2000), 64(5), 1041-1043 report the results of a study wherein the α-amylase inhibiting properties of tea extract were compared to that of structurally related citric acid, which is said to be a known inhibitor of fungal α- amylase.


US 4,477,434 describes medicinal compositions, foods and beverages, comprising a combination of papain and citric acid, having therapeutic effects on diseases of the circulatory system and the digestive system. Diseases of the circulatory system are said to include diabetes, hemorrhoids, hypertension, gout. Diseases of the digestive system mentioned in the patent include hypertrophy of the liver, hepatitis and pancreatitis. The effect of citric acid on the intestinal absorption of carbohydrates it not discussed in this patent.

Detailed description of the invention

One aspect of the present invention relates to a method of inhibiting intestinal absorption of carbohydrates in mammals, which method comprises orally administering a dietetic

preparation to such mammal, said preparation containing α -hydroxy carboxylic acid component, whose intestinal absorption is sodium dependent, in an amount equivalent to at least 1 wt.% citric acid, so as to provide α -hydroxy carboxylic acid component in an amount which is therapeutically effective to achieve inhibition of intestinal absorption of carbohydrate.

The term "inhibition" should not be interpreted restrictively, i.e. in the context of this application it encompasses prevention as well as suppression (or reduction) of intestinal absorption of carbohydrate, in particular as a result of carbohydrase inhibition. An α -hydroxy carboxylic acid is a carboxylic acid wherein the α -carbon atom is substituted with a hydroxy group. These acids can be represented by the general formula:



wherein R_1 and R_2 are independently selected from a hydrogen atom, a $\text{C}_1 - \text{C}_5$ alkyl group, a $\text{C}_6 - \text{C}_{12}$ aryl group, a heterocyclic $\text{C}_6 - \text{C}_{12}$ cycloalkyl- or -aryl group, a carboxylic group or a $-\text{CH}_2\text{COOH}$ group. Preferably R_1 and R_2 are independently selected from a hydrogen atom, a $\text{C}_1 - \text{C}_5$ alkyl group, a carboxylic group or a $-\text{CH}_2\text{COOH}$ group. The α -hydroxy carboxylic acids employed are most effective if they contain less than 12 carbon atoms, preferably between 3 and 10 carbon atoms, more preferably between 3 and 6 carbon atoms. In addition the total number of hydroxyl groups preferably does not exceed 4.

The term α -hydroxy carboxylic acid component encompasses the α -hydroxy carboxylic acid itself, precursors of said acid and metabolites of the acid which display a similar inhibiting functionality. The term mammals includes all warm blooded vertebrates.

Preferably the present method is applied to humans or pets such as dog, cat and rabbit.

Whether or not the absorption of a specific α -hydroxy carboxylic acid is sodium dependent can be determined in an in vitro model of epithelium cells lining the intestinal tract. Such methods are well known in the art and often performed in so called Ussing chambers. Sodium dependency of absorption may also be determined by an in vivo marker perfusion technique as described by Patra et al., "Enhanced sodium absorption by citrate: an in vivo perfusion study of rat small intestine", J. Pediatr Gastroenterol Nutr (1990) 11, 385-388.

The discovery by the current inventors that α -hydroxy carboxylic acids whose intestinal absorption is sodium dependent, not only stimulates rehydration, thereby preventing dehydration, but also inhibits intestinal α -amylase, has made it possible to develop a method of inhibiting intestinal carbohydrate absorption which method does not suffer from the adverse side effects normally occurring in known compositions having such action.

Glucose is absorbed in the gastrointestinal tract in a sodium dependent manner causing hydration of the intestinal cells. In the absence of high concentrations of glucose and other monosaccharides, e.g. as a result of inhibition of intestinal carbohydrase enzymes, the sodium uptake is reduced, resulting in a decreased water absorption from the gastrointestinal tract, potentially followed by adverse side effects such as diarrhoea. The α -hydroxy carboxylic acid component used in the present method is absorbed in the gastrointestinal tract in a sodium dependent way, thereby increasing the sodium concentration of the gastrointestinal cells. The increased cellular sodium concentration will increase the intracellular osmotic value, which again will induce intestinal water absorption, i.e. rehydration. Thus the α -hydroxy carboxylic acid component which is absorbed in a sodium dependent way offers the advantage that it counteracts the reductions of sodium absorption induced by the carbohydrase inhibiting action of the present dietetic preparation.

Inhibition of digestive enzymes often results in the excretion of intestinal fluid in the faeces, e.g. in the form of diarrhoea, resulting in a loss of intestinal acidic compounds and

intestinal water. The loss of intestinal acidic compounds increases the pH of the intestine, resulting in several adverse side effects, such as cellular damage to the digestive tract and inhibition of conversion of proenzyme pepsinogen to pepsin, which subsequently interferes with protein breakdown. Additionally, a rise of the intestinal pH stimulates the proliferation and growth of pathogenic bacteria in the digestive tract, such as *Escherichia coli*, *Clostridium* species and *Bacterioides*. Generally, the pathogenic bacteria are known to grow in the intestine when the pH is in the range of 5 or more, whereas the bacteria are inhibited at a pH in the range of 3.6 or below. Oral administration of α -hydroxy carboxylic acid component whose absorption is sodium dependent will minimise dehydration and will thus prevent or suppress the proliferation of intestinal pathogenic bacteria caused by the inhibition of intestinal carbohydrase enzymes.

Without wishing to be bound by theory, the inventors believe that the present α -hydroxy carboxylic acid component stimulates rehydration through the intestinal co-transport of the acid and sodium. It has been shown that, for instance, citrate uptake by brush border membranes occurs by a $\text{Na}(+)$ -dependent transport mechanism (Wolffram et al., "Transport of tri- and dicarboxylic acids across the intestinal brush border membrane of calves", *J. Nutr.* (1990), 120(7), 767-774). Furthermore, in humans, citrate has been shown to stimulate absorption of sodium and consequently water absorption from the human jejunum (Rolston et al, "Acetate and citrate stimulate water and sodium absorption in the human jejunum", *Digestion*, (1986), 34(2), 101-104). The sodium co-transported with the citrate is believed to induce an increase of intracellular osmotic value, resulting in water transport from the intestine to the cells, i.e. rehydration.

The present method produces particularly good results if the α -hydroxy carboxylic acid component is provided in a daily amount equivalent to at least 0.25 mg, preferably at least 0.5 mg citric acid per kg of bodyweight of the mammal. Most preferably the α -hydroxy carboxylic acid component is provided in a daily amount equivalent to at least 1 mg, more preferably equivalent to at least 3 mg citric acid per kg of bodyweight.

The amount of α -hydroxy carboxylic acid component which is equivalent to a given amount of citric acid can be established as follows:

1. calculate the equivalent molar amount of citric acid,
 2. multiply the molar amount by a factor 3
 - 5 3. divide the result of the multiplication by the number of carboxylic groups present in the α -hydroxy carboxylic acid
 4. calculate for the α -hydroxy carboxylic acid component how many mg's are equivalent to the molar amount obtained from 3.
- 10 In accordance with the method of the invention, preferably the dosage form is chosen such that preparation can be administered in dosage units of between 0.025 and 200 g, more preferably between 0.1 and 100 g, and most preferably between 0.25 and 50 g.

For a human being, a single dosage unit preferably comprises α -hydroxy carboxylic acid
15 component in an amount equivalent to at least 40 mg, more preferably at least 100 mg, most preferably above 250 mg citric acid. Meals, such as breakfast, lunch, and dinner usually contain digestible carbohydrates in amounts of 20 grams or more. According to a preferred embodiment, the dietetic preparation used in the method according to the invention is directed towards the inhibition of the absorption the digestible carbohydrates
20 from meals. In order to obtain sufficient inhibition of carbohydrate absorption following the consumption of such a meal, the preparation preferably contains α -hydroxy carboxylic acid component in an amount equivalent to at least 150 mg, more preferably at least 200 mg citric acid. To ensure a sufficient rehydration when additional carbohydrase inhibitors or monosaccharide uptake inhibitors are present in the dietetic preparation used
25 in the method according to the invention, the dietetic preparation preferably contains at least α -hydroxy carboxylic acid component in an amount equivalent to at least 100 mg, more preferably at least 150 mg, most preferably at least 200 mg citric acid.

If the present dietetic preparation is used to reduce the absorption of carbohydrates
30 originating from a separately consumed foodstuff (hereinafter referred to as dietary carbohydrates), it is undesirable for said preparation to contain large amounts of

digestible carbohydrates as this will counteract the objective of achieving inhibition of carbohydrate absorption. Hence, in a preferred embodiment, the dietetic preparation comprises less than 60 wt.%, more preferably less than 40 wt.%, even more preferably less than 25 wt.% and especially preferred, less than 10 wt.% digestible carbohydrates calculated on dry weight of the preparation. Unless indicated otherwise, the percentages mentioned in this application apply to the consumable part of the preparation, e.g. not including packaging material.

According to another preferred embodiment the caloric value of digestible carbohydrates is less than 50%, preferably less than 25% and more preferably less than 10% of the total caloric value of the preparation according to the invention. In yet another preferred embodiment the amount of α -hydroxy carboxylic component, calculated as citric acid equivalent, exceeds the amount of digestible carbohydrates in the preparation. More preferably the amount of α -hydroxy carboxylic component, calculated as citric acid equivalent, is at least twice, preferably at least thrice as high as the amount of digestible carbohydrates in the preparation.

Transport of glucose in a cell is accompanied by transport of Na^+ and water absorption. Inhibition of glucose absorption will normally lead to reduced water absorption which again may give rise to diarrhoea. Although an α -hydroxy carboxylic component such as citric acid will stimulate water transport, i.e. rehydration, it is undesirable for the present preparation to contain large amounts of water as this will increase the risk of diarrhoea and other adverse side effects. Hence, in a preferred embodiment, the dietetic preparation used in the method of the invention contains less than 95 wt.%, preferably less than 90 wt.%, even more preferably less than 75 wt.% and most preferably less than 25 wt.% water.

In order for the present preparation to be effective in inhibiting carbohydrate absorption said preparation should deliver citric acid into the intestine in a rather concentrated form, i.e. at least 1% by weight of the preparation. Preferably the dietetic preparation used in the present method contains α -hydroxy carboxylic acid component in an amount

equivalent to at least 2 wt.%, more preferably at least 5 wt.% and most preferably at least 8 wt.% citric acid. Generally the preparation will contain the α -hydroxy carboxylic acid component in an amount which is equivalent to less than 95 wt.% citric acid, preferably less than 90 wt.% citric acid and more preferably less than 75 wt.% citric acid.

5

According to a very preferred embodiment of the invention the α -hydroxy carboxylic acid component is citric acid component. The term "citric acid component" as used herein, encompasses citric acid, precursors of citric acid and metabolites of citric acid which display a similar inhibiting functionality. In case the α -hydroxy carboxylic acid component is citric acid component the amount of citric acid component which is equivalent to a given amount of citric acid is easily established by calculating which amount of the citric acid component would liberate said given amount of citric acid, assuming that the citric acid component is fully converted, i.e. releases all citric acid contained therein.

10

15

Citric acid (2-Hydroxy-1,2,3-propanetricarboxylic acid) is a naturally occurring fruit acid, produced commercially by microbial fermentation of a carbohydrate substrate is widely available, e.g. as monohydrate or anhydrous citric acid and is the most widely used organic acidulant and pH-control agent in foods, beverages, pharmaceuticals and technical applications. However, it has not been recognised before to have the advantageous capability of inhibiting carbohydrate absorption.

20

In Europe, citric acid monohydrate and anhydrous are listed as generally permitted food additives (E 330) and may be added to all foodstuffs. The US Food and Drug Administration (FDA) affirmed citric acid as GRAS (generally recognized as safe) and permitted the use in food according to current GMP (CFR § 182.1033), without setting an upper limit.

25

The dietetic preparation in accordance with the invention may suitably take the form of tablets, capsules, powders, foodstuffs (e.g. nutritional bars or desserts). According to a preferred embodiment of this invention, the α -hydroxy carboxylic acid component is

30

ingested in the form of a tablet or capsule, having a weight between about 25 mg and 3000 mg, preferably between about 100 mg and 2500 mg, most preferably between 200 and 2000 mg. In order to prevent adverse taste effects, particularly in case the acid component is administered in a concentrated way in the form of a capsule or a tablet, said
5 tablet or capsule is preferably coated in such a way that the acid component is not released in the mouth. Hence, in a preferred embodiment, the α -hydroxy carboxylic acid is orally administered in a solid unit dosage form wherein at least 95 % of the α -hydroxy carboxylic acid reaches the stomach in solid state, more preferably at least 98 %.

Effectiveness of the α -hydroxy carboxylic acid component is further enhanced when the
10 α -hydroxy carboxylic acid is specifically delivered in the small intestine, e.g. by incorporating the α -hydroxy carboxylic acid component in a tablet or capsule having a stomach acid resistant coating, e.g. coated with an acid resistant polymer, or alternatively by employing an α -hydroxy carboxylic acid precursor which releases most of the α -hydroxy carboxylic acid in the small intestine.

15

In a preferred embodiment of the present method the α -hydroxy carboxylic acid is delivered in the intestine in a largely protonated form. Thus, preferably at least 50%, more preferably at least 75% of the α -hydroxy carboxylic acid in the present preparation is protonated. In case the acid contains more than one carboxylic group these percentages
20 are to be applied to the total number of carboxylic groups. In order to ensure that the carboxylic acids remain protonated even when entering the mildly acidic intestinal tract, it may be advantageous to include an acidic buffer with a buffer pH at which the acid is largely protonated.

25

Best results are obtained with the present method if the preparation is administered no more than 60, preferably no more than 30 minutes before or after consumption of a foodstuff containing a significant amount, e.g. at least 20 g, of digestible carbohydrates. Thus the α -hydroxy carboxylic acid is allowed to move through the intestine together with the foodstuff, thereby effectively preventing enzymatic digestion of the saccharides
30 contained therein, and simultaneously preventing dehydration.

The term digestible carbohydrates as used herein includes carbohydrates which can be absorbed directly by the intestine of the mammal as well as carbohydrates which are readily degraded within the intestine to such directly absorbable carbohydrates.

5 Carbohydrates that are readily degraded within the intestine are those carbohydrates that can be digested by one or more of the salivatory, pancreatic or brush border enzymes of a given mammal. In case of humans these enzymes include glucoamylase (glucosidase), isomaltase, α -limit dextrinase, sucrase, lactase, pancreatic amylase and/or salivatory amylase.

10

The present method aims to inhibit intestinal carbohydrate absorption. Inhibition of intestinal carbohydrate absorption within the context of this invention refers specifically to a decrease of the intestinal enzyme activity that is associated with the hydrolysis of di-, tri-, oligo- and polysaccharides. Thus the present method leads to a decreased net
15 absorption of monosaccharides from dietary digestible carbohydrates or to an absorption of monosaccharides over an increased surface area of the small intestine (i.e. absorption spread out over a longer period of time).

20 The present method is particularly suitable for (prophylactically) treating obesity as the reduction in carbohydrate absorption will usually also lead to a reduction in production of body fat. Another advantageous application of the method is its use for suppressing fluctuations in blood glucose levels, which is particularly beneficial for diabetics. Suppression of blood glucose fluctuations, and particularly the blood glucose 'peaks', is also of benefit for obese people as the resulting gradual absorption of carbohydrates
25 usually leads to less body fat formation than is observed for rapid absorption of the same amount of carbohydrates.

30 The dietetic preparation according to the invention preferably contains α -hydroxy carboxylic acid component in an amount equivalent to at least 25 mg, more preferably equivalent to between 50 and 3000 mg, and most preferably equivalent to between 200 and 2000 mg citric acid.

The citric acid component used in accordance with the invention is preferably selected from the group consisting of citric acid, precursors of citric acid capable of liberating citric acid under the influence of the conditions prevailing in the gastrointestinal tract and mixtures thereof. More preferably the citric acid component is selected from the group consisting of citric acid, citric acid salts, citric acid esters and mixtures thereof.

The dietetic preparation of the present invention is preferably packaged as an oral dosage unit containing between 0.025 and 200 g, more preferably between 0.1 and 100 g and most preferably between 0.3 and 10 g of the preparation.

In another preferred embodiment the dietetic preparation contains at least 10 wt.% α -hydroxy carboxylic acid component, less than 50 wt.% water and less than 10 wt.% digestible carbohydrates. Both the presence of large amounts of water and digestible carbohydrates are undesirable as they counteract the efficacy of the present method and preparation. In an even more preferred embodiment the preparation contains less than 10 wt.% water.

Preferably the present preparation is designed in such a way that it will deliver α -hydroxy carboxylic acid component in a concentrated form so it may easily be ingested concurrently with the consumption of a foodstuff. Hence the present preparation is advantageously packaged as an oral dosage unit containing between 0.1 and 5 g of the preparation and containing the α -hydroxy carboxylic acid component in an amount equivalent to between 100 and 2500 mg, preferably between 200 and 2000 mg citric acid.

25

Another aspect of the invention relates to a dietetic preparation in the form of an oral dosage unit of between 0.1 and 100 grams, said preparation containing between 2 and 90 wt.% of α -hydroxy carboxylic acid component, whose intestinal absorption is sodium dependent, between 1 and 80 wt.% of a carbohydrate absorption inhibitor selected from the group consisting of polyphenols, gymnemic acid and mixtures thereof and between 97 and 9 wt.% of pharmaceutically acceptable excipient. Preferably the present

30

preparation contains between 10 and 50 wt.% of the carbohydrate absorption inhibitor. More preferably the present preparation contains between 10 and 80 wt.% of plant polyphenols.

- 5 Tablets and equivalent solid and semi-solid oral dosage forms can suitably contain excipients such as hydroxypropylmethyl cellulose, other cellulosic materials, starch, polyvinyl-pyrrolidone, lactose and other sugars, starch, dicalcium phosphate, starch polymers, stearates, talc etc.
- 10 In yet another embodiment the present invention relates to a kit containing at least 10 dosage units comprising a dietetic preparation according to the invention, wherein the weight of the individual dosage units is between 0.3 and 10 g and said dosage units contain the α -hydroxy carboxylic acid component in an amount equivalent to between 100 and 2500 mg citric acid.

15

Carbohydase inhibitors

- The dietetic preparation used in the present method may advantageously comprise one or more known carbohydase enzyme inhibitors, since these inhibitors may complement the desirable effect of the α -hydroxy carboxylic acid component. In a preferred embodiment
- 20 of this invention the dietetic preparation for inhibition of intestinal carbohydrate absorption further comprises a second carbohydase inhibitor, preferably an intestinal α -glucosidase inhibitor, in an amount effective to provide synergistic action besides the α -amylase inhibition by the α -hydroxy carboxylic acid. Co-administration of the α -hydroxy carboxylic acid component and a second carbohydase inhibitor (other than the α -
- 25 hydroxy carboxylic acid component) offers the benefit of less side effects, such as flatulence and diarrhea, compared to the use of α -hydroxy carboxylic acid alone. Exemplary and preferred carbohydase inhibitors used in accordance with the present invention include Phaseolus vulgaris (phaseolamin), roselle tea, lotus, arabinose, inosine, adenosine, evening primrose extract, banaba extract, Epimedium extract, indigestible
- 30 dextrin and polyphenols.

The combination of α -amylase inhibitors and α -glucosidase inhibitors provide a potent blend of carbohydrase inhibitor. Such combinations are known in the art, however these combinations exhibit pronounced side effects, particularly when compared to a single carbohydrase inhibitors. These side effects include severe diarrhea, dehydration, flatulence and loss of intestinal fluids (see above). Such adverse side effects are observed to a much lower degree when the present method is employed, i.e. using a preparation containing an effective amount of α -hydroxy carboxylic acid component.

The supplementary intestinal carbohydrase inhibitor, preferably α -glucosidase inhibitor, to be used in combination with citric acid is preferably derived from plant material, preferably herbal plant material. The plant derived material used preferably comprises polyphenols. More preferably the plant derived material is an extract of a plant material in which the content of polyphenols is increased compared to the content of polyphenols naturally occurring in stems, leafs, roots and/or seeds of the same plant material.

Epimedium

According to a preferred embodiment of the present invention, the carbohydrase inhibitor co-administered with the α -hydroxy carboxylic acid is *Epimedium* plant material, preferably *Epimedium brevicorum* plant material. It was surprisingly found by the present inventors that *Epimedium* plant material inhibits intestinal carbohydrase. Hence, in a particularly preferred embodiment, the present invention provides a dietetic preparation comprising a combination of the α -hydroxy carboxylic acid and *Epimedium* plant material. This dietetic preparation is particularly effective in a method for the reduction of intestinal carbohydrate absorption, with the additional benefit of producing significantly less side effects, such as flatulence and diarrhea, compared to the use of α -hydroxy carboxylic acid alone. In a further preferred embodiment, a solvent extract of *Epimedium brevicorum* is used in the present method.

The *Epimedium* plant material is preferably administered in a daily amount of 10 mg to 5 g, preferably in a daily amount of 50 mg to 1000 mg.

Polyphenols

According to a preferred embodiment of the current invention, the carbohydrase inhibitor, preferably α -glucosidase inhibitor, are plant derived polyphenols, selected from the group consisting of catechins or derivatives thereof, anthocyanidins, proanthocyanidins, procyanidin and cyanidin, which are exemplary and preferably obtained from green tea (*Camellia sinensis*) or grape (*Vitis vinifera*). Preferably such plant extracts have a significant content of polyphenols, increasing the effectiveness as an intestinal carbohydrase inhibitor. However, oral intake of polyphenols, especially extracts, will result in a decreased absorption of water in the intestine, resulting in many cases in diarrhea and loss of intestinal fluid, potentially followed by proliferation and growth of undesirable intestinal bacteria and damage to the intestinal cells. Such adverse side effects of polyphenol ingestion, especially compositions having high polyphenol content, will be prevented by the co-administration of α -hydroxy carboxylic acid component.

Herbal extracts comprising polyphenols are known in the art. Most suitable for use in the method and preparation according to the present invention, are extracts comprising more than about 10 wt.% polyphenols based on the dry weight of the plant extract, preferably above about 25 wt.% polyphenols even more preferably above about 50 wt% polyphenols and most preferably above about 75 wt% polyphenols.

Green tea extract

The dietetic preparation of the present invention may advantageously contain green tea extract as a source of polyphenols. Green tea catechins or derivatives thereof (including monomers, polymers or gallated monomers or polymers of catechin) have been described to inhibit the intestinal α -glucosidase enzyme (Matsui et al, Biosci Biotechnol Biochem 1996 Dec;60(12):2019-22). Additionally green tea has been ingested for centuries by human beings and can therefore be regarded as very safe.

Preferably green tea extracts used in the preparation according to the invention comprise more than 20 wt.%, more preferably more than 40 wt.% catechins expressed as

epigallocatechin gallate based on the total dry weight of the green tea extract, so as to provide sufficient carbohydrase inhibitory action. Preferably the green tea extract is administered in a daily amount of between 10 mg and 5 g, more preferably in a daily amount of between 50 mg and 2.5g.

5

Grapeseed extract

To further stimulate the action of α -hydroxy carboxylic acid or the combination of such acid and polyphenols (e.g. green tea polyphenols), grape polyphenols can be added to the formulation. Grape polyphenols are preferably obtained from the seeds. Suitable for use
10 in the composition according to the invention is grape seed powder, however, according to a preferred embodiment grape seed (powder) extract is used.

Grape seed powder or extract preferably comprises an effective amount of grape polyphenols, preferably one or more selected from anthocyanidins, proanthocyanidins,
15 procyanidin and cyanidin. The grapeseed powder or extract preferably comprises more than about 10 wt.% grape polyphenols based on the dry weight of the grape seed powder or extract, preferably more than about 25 wt.% polyphenols, even more preferably more than about 50 wt.% polyphenols, most preferred above about 75 wt.% polyphenols. Preferably the grape seed powder or extract is administered in a daily amount of between
20 10 mg and 5 g, more preferably in a daily amount of between 50 mg and 2.5 g.

Monosaccharide absorption inhibitor

Advantageously, the preparation according to the present invention comprises a component capable of inhibiting monosaccharide uptake in the intestine. Such a
25 component, when used alone, can also produce the adverse side effects mentioned above, i.e. diarrhea, flatulence etc. When used in combination with α -hydroxy carboxylic acid component such undesirable effects will be reduced or prevented.

The action of the monosaccharide uptake inhibitor will further enhance the effects of
30 inhibition of the carbohydrate absorption and/or increase the intestine surface area across which the carbohydrate is absorbed. Thus the co-administration of a monosaccharide

uptake inhibitor will increase the performance of the present preparation. The inhibition of uptake of monosaccharides by the monosaccharide uptake inhibitor, increases the monosaccharide/digestible carbohydrate ratio, thereby decreasing the conversion rate of digestible carbohydrates to monosaccharides and thus providing the α -hydroxy carboxylic acid and other carbohydrase inhibitors the opportunity to further inhibit the carbohydrase activity.

The substances capable of inhibiting monosaccharide uptake used in a preferred embodiment according to this invention are capable of decreasing transport of monosaccharide over the intestinal wall without the necessity for a decrease in intestinal glucose concentration. However, excess content of monosaccharide uptake inhibitor in the dietetic preparation according to the invention might interfere with the rehydration action of the α -hydroxy carboxylic acid component. Monosaccharide uptake inhibitors which may advantageously be employed in the present method include fibrous and non-fibrous monosaccharide uptake inhibitors.

In case non-fibrous monosaccharide uptake inhibitors are employed, the weight ratio monosaccharide inhibitor to α -hydroxy carboxylic acid component is between about 10:1 and 1: 250, more preferably between 1:1 and 1:100, and most preferably between 1:5 and 1:50. Preferably the non-fibrous monosaccharide uptake inhibitor is of plant origin. Preferably such a substance is of a plant origin, of which the safety has been well established. Exemplary non-fibrous monosaccharide uptake inhibitors are peppermint (oil), procyanidin, galloyl residues or can be obtained from *Gymnema* species, *Azadirachta indica*, *Eugenia uniflora*, *Ginseng radix*, soy. An especially preferred compound for such action to be used in the preparation according to the invention is gymnemic acid. This substance can, for example, be found in plants of the species *Gymnema*, e.g. *Gymnema sylvestre*. According to a further preferred embodiment the composition comprises at least 5 wt.%, more preferably at least 10 wt.% and most preferably at least 20 wt.% gymnemic acid calculated on dry weight of the monosaccharide uptake inhibitor.

According to a further preferred embodiment of the invention the dietetic preparation comprises a fibrous monosaccharide uptake inhibitor, such as indigestible plant carbohydrates, particularly plant fibres. Preferably the fibrous monosaccharide uptake inhibitor comprises an effective amount of soluble fibre selected from the group consisting of pectin, guar gum, Konjak mannan, locust bean gum, oat fibre, inulin and mixtures thereof.

Use

The preparation according to the invention can be used advantageously by subjects having the desire or need to reduce carbohydrate absorption, or desiring to decrease fluctuations in blood glucose level. The preparation may be used as such in weight management programs or can be included in compositions designed for weight management, for athletes having the desire to decrease carbohydrate absorption and for preventing the adverse side effects of craving, etc.

Compositions that aim to meet the above objectives are known in the art and are often referred to as "carbohydrate cutters", "carb-cutters", "carbohydrate blockers", "carb blockers", compositions providing balanced and/or healthy blood sugar levels, (high) protein bars and the like.

EXAMPLES

Example 1

A oral nutritional supplement in the form of a capsule comprising 500 mg citric acid, to be administrated before, during or shortly after carbohydrate containing meal or snack.

Example 2:

A oral nutritional supplement in the form of a capsule comprising

200 mg green tea extract (75 wt.% polyphenols based on the weight of the green tea extract)

500 mg citric acid

to be administrated before, during or shortly after carbohydrate containing meal or snack.

Example 3:

- 5 A oral nutritional supplement in the form of a capsule comprising
250 mg *Gymnema sylvestre* extract (25 wt.% gymnemic acid based on the weight
of the *Gymnema sylvestre* extract)
500 mg citric acid
to be administrated before, during or shortly after carbohydrate containing meal or snack.

10

Example 4:

- A oral nutritional supplement in the form of a capsule comprising
250 mg *Gymnema sylvestre* extract (25 wt.% gymnemic acid based on the weight
of the *Gymnema sylvestre* extract)
15 100 mg green tea extract (75 wt.% polyphenols based on the weight of the green
tea extract)
50 mg Grapeseed extract (90 wt.% polyphenols based on the weight of the
grapeseed extract)
300 mg citric acid
20 to be administrated before, during or shortly after carbohydrate containing meal or snack

Example 5

- A dietetic food preparation in the form of a coated tablet, to be ingested within 45
minutes prior to the consumption of a foodstuff containing a significant amount of
25 digestible carbohydrates, said tablet comprising:
300 mg citric acid
1000 mg Konjak mannann

Example 6

A placebo controlled, double-blind, randomized, parallel study was conducted to evaluate the tolerance of a composition containing citric acid, grape seed extract, green tea extract and *Gymnema Sylvestre* leave extract.

Study population

Volunteers were recruited in Wageningen (the Netherlands) and surroundings. Posters at several locations at the university and student flats and advertisements in local newspapers were used. Inclusion criteria for study participation were: Body Mass Index (BMI) between 20 and 24.9 kg/m², age between 18 and 45 years. Exclusion criteria were: diabetes mellitus, chronic intestinal diseases or related symptoms (present and history), acute diarrhea during the previous month, constipation, use of medication affecting the gastrointestinal tract (e.g. antibiotics, laxatives), unusual dietary habits (e.g. specific diets, vegans), pregnancy or intention to get pregnant.

During the screening visit body weight and body height were determined. Body weight was measured to the nearest 0.1 kg using a precision scale without shoes with subjects dressed in light clothing. Height was determined to the nearest cm without shoes. BMI was calculated from weight and height: $\text{weight(kg)}/(\text{height(m)})^2$. Depending on this result it was decided whether the subject could participate in the study.

Seventeen healthy subjects (6 males, 11 females) in the age of 27 ± 5 years (mean \pm SD) and BMI 22.2 ± 1.8 kg/m² (mean \pm SD) were recruited. The study was explained by the investigator. All subjects signed informed consent forms prior to their entry into the study.

Study design

Participants were randomized over 2 groups. Each group received Carbcutter or Placebo (ingredients of a single dose of Carbcutter and Placebo are provided in Table 1 below). Tolerance of the product was determined for two weeks.

On the first study day, after a 12h overnight fast, a blood sample was obtained to measure safety parameters. To test the tolerance of the products, the subjects were asked to consume one of the products (Carbucutter or Placebo) for two weeks. A single dose of the products was ingested with each of the two main meals; i.e. two times a day. At the end of each day, the subjects were asked to fill in the provided questionnaire about gastrointestinal complaints, stool frequency and stool consistency. At the end of the two weeks of tolerance, after a 12h overnight fast, body weight was measured and a blood sample was taken to measure safety parameters. As safety endpoints, changes in liver and kidney function before and after the tolerance period were determined.

Test products

The product ingredients are specified in Table 1

TABLE 1

Ingredient	Supplement (g)	Placebo (g)	Characteristics	Supplier
Citric acid	300	0		Citric acid anhydrous Citrique Belge N.V.
Green tea leave extract	100	0	Polyphenols 95.7% Epigallo catechin gallate 35%	P.L. Thomas & Co., Inc.
Grape seed extract	50	0	Phenolics (gallic acid equivalents) 98.7% (min 90g GAE/100g)	Polyphenolics
Gymnema Sylvestre leave extract	200	0	Gymnemic acid 28.24% (25- 30%)	Sabinsa corporation
Calcium Carbonate	0	650		
Total	650	650		

Serving size

1 capsule per meal. Capsules had to be taken with the two main meals, i.e. 2 capsules a day.

Questionnaire

Gastrointestinal complaints concerning flatulence, bloating, abdominal pains or cramps, eructation, nausea, vomiting and stomach pains or cramps were rated on a 5-point scale. Stool consistency was rated on a 5-point scale based on the scale by Heaton *et al.* (Gut 1992;33(6):818-24): watery-soft, pudding like-soft, snake like-dry, cylindric-dry, hard pellets. Stool frequency was also recorded. Other adverse effects could be recorded in the questionnaires.

Biochemical measurements

As safety parameters the following blood parameters were measured at the beginning and at the end of the study: aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactic acid dehydrogenase (LDH), creatinine, gamma-glutamyl transferase (GGT), alkaline phosphatase, and urea nitrogen (BUN). Blood samples were collected in clotting tubes and centrifuged after clotting. Plasma samples were analyzed according to standard laboratory methods.

Statistical analysis

Differences between groups for the questionnaire were analyzed using the non-parametric Mann-Whitney *U* test for unpaired observations. For the categorical data with two categories, a comparison between the two treatment groups was performed using the Fishers' exact test. The safety laboratory values were statistically tested using the two-sample Mann-Whitney *U* test for unpaired samples. Statistical differences were assumed when $P < 0.05$.

Results

Questionnaire

Following administration of the Carbcutter, no significant effects on bloating, abdominal pain, stomach ache, eructations, nausea, frequency of stools/day, consistency of all the stools, general physical well being and vomiting were observed compared to placebo.

Also no other adverse events were reported. For Results of the questionnaire, the mean scores over 14 days for the two groups results, see Table 2.

TABLE 2

	Carbucutter ^a	Placebo ^a	P-value
Flatulence ^b	1.7	1.7	0.650 ^f
Abdominal pain ^b	1.2	1.3	0.395 ^f
Bloating ^b	1.2	1.6	0.076 ^f
Stomach ache ^b	1.1	1.2	0.892 ^f
Eructations ^b	1.1	1.0	0.239 ^f
Nausea ^b	1.1	1.2	0.445 ^f
Frequency of stools/day	1.4	1.5	0.941 ^f
Consistency of all the stools ^c	3.2	3.3	0.459 ^f
General physical well being ^d	7.9	7.3	0.230 ^f
Vomiting ^e	2.0	2.0	0.452 ^g
Other adverse events ^e	1.8	1.7	0.427 ^g
Use medication ^e	2.0	1.9	0.292 ^g

5 ^aMeans of all variables were given for the tolerance period of 14 days.

^b range 1 to 5: 1 = not at all, 5 = continuous

^c 1 = watery, 2 = pudding like-soft, 3 = snake like-soft, 4 = cylindric-dry, 5 = hard pellets.

^d range 1 to 10: 1 = very bad, 10 = very good

^e 1 = yes, 2 = no

10 ^f Differences between groups were analyzed using the non-parametric Mann-Whitney *U* test for unpaired observations (with corrections for ties if applicable). $P < 0.05$ was considered to be significant.

^g Differences between groups were analyzed using the Fisher's exact test. $P < 0.05$ was considered to be significant.

15 *Safety parameters*

As safety endpoints, changes in liver function and kidney function before and after the tolerance period were determined. In Table 3 mean changes in kidney and liver enzyme levels in the two groups \pm SEM are shown. Differences between the two groups were not significantly different except for Urea nitrogen. Probably this was due to the significant
20 difference already found at baseline characteristics for Urea nitrogen.

TABLE 3

	Carbucutter	Placebo	P-value
ASAT (U/L)	1.3 ± 2.3	-1.7 ± 1.2	0.300
ALAT (U/L)	5.4 ± 1.9	5.7 ± 0.9	0.905
LD (U/L)	41.7 ± 53	-36.4 ± 8.7	0.133
Creatinine ($\mu\text{mol/L}$)	-6.6 ± 1.7	-5.7 ± 3.0	0.813
GGT (U/L)	1.5 ± 0.6	0.3 ± 0.3	0.206
Alkaline phosphatase (U/L)	0.1 ± 3.5	2.7 ± 1.6	0.651
Urea nitrogen (mmol/L)	0.16 ± 0.2	-0.7 ± 0.3	0.040

Conclusion

- 5 Following administration of the supplement, no significant effects on flatulence, bloating, abdominal pain stomach ache, eructations, nausea, frequency of stools/day, stool consistency, general physical well being and vomiting were observed compared to placebo. So administration of the product for 14 days was well-tolerated.

Claims

1. Use of α -hydroxy carboxylic acid component in the manufacture of a dietetic preparation for use in a method for inhibiting intestinal absorption of carbohydrates in a mammal, which method comprises orally administering the dietetic preparation to such mammal, said preparation containing α -hydroxy carboxylic acid component, whose intestinal absorption is sodium dependent, in an amount equivalent to at least 1 wt.% citric acid, so as to provide α -hydroxy carboxylic acid component in an amount which is therapeutically effective to achieve inhibition of intestinal absorption of carbohydrate.
2. Use according to claim 1, wherein the α -hydroxy carboxylic acid component is citric acid component.
3. Use according to claims 1 or 2, wherein the method comprises providing the α -hydroxy carboxylic acid component in a daily amount equivalent to at least 0.5 mg citric acid per kg of bodyweight.
4. Use according to any one of the preceding claims, wherein the preparation contains less than 90 wt.% water.
5. Use according to any one of the preceding claims, wherein the preparation contains the α -hydroxy carboxylic acid component in an amount equivalent to at least 2 wt.% citric acid.
6. Use according to any one of the preceding claims, wherein the preparation is administered no more than 60 minutes before or after consumption of a foodstuff containing at least 20 g of digestible carbohydrates.

7. Use according to any one of the preceding claims, wherein the preparation comprises less than 60 wt.% digestible carbohydrates based on dry weight of the preparation.
- 5 8. Use according to any one of the preceding claims, wherein the amount of α -hydroxy carboxylic acid component, calculated as citric acid equivalent, exceeds the amount of digestible carbohydrates in the preparation.
9. Use according to any one of the preceding claims, wherein the method comprises
10 administration of the preparation in dosage units of between 0.1 and 100 g.
10. Use according to any one of the preceding claims, wherein the preparation contains α -hydroxy carboxylic acid component in an amount equivalent to between 50 and 3000 mg citric acid.
- 15 11. Use according to any one of the preceding claims, wherein the preparation additionally contains an intestinal carbohydrase inhibitor other than the α -hydroxy carboxylic acid component.
- 20 12. Use according to claim 11, wherein the preparation additionally contains an intestinal carbohydrase inhibitor selected from the group consisting of Phaseolus vulgaris (phaseolamin), roselle tea, lotus, arabinose, inosine, adenosine, evening primrose extract, banaba extract, Epimedium extract, indigestible dextrin, polyphenols and mixtures thereof.
- 25 13. Use according to claim 12, wherein the preparation additionally contains Epimedium extract.
14. Use according to any one of the preceding claims, wherein the preparation
30 additionally contains a monosaccharide uptake inhibitor, said absorption reducing

component being selected from the group consisting of gymnemic acid, pectin, guar gum, Konjak mannan, locust bean gum, oat fibre, inulin and mixtures thereof.

5 15. Use according to any one of the preceding claims, for the (prophylactic) treatment of obesity.

16. Use according to any one of the preceding claims, for reducing blood glucose fluctuations.

10 17. Dietetic preparation in the form of an oral dosage unit of between 0.1 and 100 grams, said preparation containing between 2 and 90 wt.% of α -hydroxy carboxylic acid component whose intestinal absorption is sodium dependent, between 1 and 80 wt.% of a carbohydrate absorption inhibitor selected from the group consisting of polyphenols, gymnemic acid, *Epimedium* plant material and mixtures thereof and between 97 and 9
15 wt.% of pharmaceutically acceptable excipient.

18. Dietetic preparation according to claim 17, comprising *Epimedium* plant material.

19. Dietetic preparation according to claims 17 or 18, wherein the oral dosage unit is a
20 tablet or capsule of between 0.3 and 10 grams.

20. Dietetic preparation according to any one of the claims 17-19, wherein the preparation contains α -hydroxy carboxylic acid component in an amount equivalent to at least 25 mg, preferably equivalent to between 50 and 3000 mg citric acid.
25

21. Dietetic preparation according to any one of the claims 17-20, wherein the preparation comprises less than 60 wt.% digestible carbohydrates calculated on dry weight of the preparation.

30 22. Dietetic preparation according to any one of the claims 17-21, wherein the α -hydroxy carboxylic acid component is selected from the group consisting of α -hydroxy carboxylic

acid, precursors of α -hydroxy carboxylic acid capable of liberating α -hydroxy carboxylic acid under the influence of the conditions prevailing in the gastrointestinal tract and mixtures thereof.

- 5 23. Dietetic preparation according to any one of the claims 17-22, wherein the α -hydroxy carboxylic acid component is citric acid component.
24. Dietetic preparation according to any one of the claims 17-23, wherein the preparation is packaged as an oral dosage unit containing between 0.1 and 100 g of the
10 preparation.
25. Dietetic preparation according to any one of the claims 17-24, wherein the preparation contains between 10 and 80 wt.% plant polyphenols.
- 15 26. Dietetic preparation according to any one of the claims 17-25, wherein the preparation additionally contains a monosaccharide uptake inhibitor, said absorption reducing component being selected from the group consisting of pectin, guar gum, Konjak mannan, locust bean gum, oat fibre, inulin, indigestible dextrin and mixtures thereof.
- 20 27. Dietetic preparation according to any one of the claims 17-26, wherein the preparation contains at least 10 wt.% α -hydroxy carboxylic acid component, less than 50 wt.% water and less than 10 wt.% digestible carbohydrates.
- 25 28. Kit containing at least 10 oral dosage units comprising the dietetic preparation according to claim 15, wherein the weight of the individual dosage units is between 0.3 and 10 g and said dosage units contain the α -hydroxy carboxylic acid component in an amount equivalent to between 100 and 2500 mg citric acid.

INTERNATIONAL SEARCH REPORT

Int. Application No.

PCT/NL 02/00394

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/19 A61K35/78 A61P3/04 A61P3/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, MEDLINE, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 1999, no. 01, 29 January 1999 (1999-01-29) & JP 10 265397 A (TOYOTAMA KENKO SHOKUHIN KK;ORUTO CORP:KK), 6 October 1998 (1998-10-06) abstract	1,2,9, 11,12, 15,17, 19, 23-26,28
X	PATENT ABSTRACTS OF JAPAN vol. 1999, no. 04, 30 April 1999 (1999-04-30) & JP 11 001431 A (NICHIIYAKU KK), 6 January 1999 (1999-01-06) abstract	1,2,15

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

30 September 2002

Date of mailing of the international search report

17/10/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Baumgärtner, H

INTERNATIONAL SEARCH REPORT

International Application No

PCT/NL 02/00394

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 1 311 015 A (HOFFMANN LA ROCHE) 21 March 1973 (1973-03-21) page 1, column 1, line 13,14,21-23 page 1, column 1, line 35,36 page 2, column 2; examples 1-3	1,2,9, 15,28
X	WO 00 00188 A (PEMBY LTD ;THOM ERLING (NO); KJELDSTADLI JARL (NO)) 6 January 2000 (2000-01-06) page 1	1,2,9, 15,28
X	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; WOODGATE DEREK E: "Double-blind study evaluating the effects on a novel herbal supplement on weight loss in overweight adults" Database accession no. PREV200100261946 XP002214082 abstract	17
X	US 6 004 610 A (TROUP JOHN P ET AL) 21 December 1999 (1999-12-21) column 2, line 29,30 column 4; example 3	2,9,12, 14,17, 23,24,26
A	DATABASE WPI Week 200112 Derwent Publications Ltd., London, GB; AN 2001-103699 XP002215206 LIU, S.: "Konjak jelly preparation" & CN 1 146 867 A (LIU S), 9 April 1997 (1997-04-09) abstract	2,14,15, 28
A	EP 0 477 161 A (INSTANTINA NAHRUNG GMBH ;SCHMIDGALL A & L DR FA (AT)) 25 March 1992 (1992-03-25) column 1, line 3-6 column 2, line 35-38 column 3, line 8-12	2,9,14
A	EP 0 856 259 A (SITIA YOMO SPA) 5 August 1998 (1998-08-05) column 5, line 40,41 column 5, line 53-55	14,26
A	WO 01 33975 A (BIJLSMA PIETER BRANDT ;GROOT JACQUES ALPHONS (NL); TIMMERMANS JOHA) 17 May 2001 (2001-05-17) page 2, line 10-12 page 2, line 31	14,26

INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/NL 02/00394

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 00 33854 A (LAERE KATRIEN VAN ;NUTRICIA NV (NL); JONG PATRICIA DE (NL)) 15 June 2000 (2000-06-15) page 8; example IV</p> <p>-----</p>	<p>12,14,26</p>

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Claims Nos.: 3-8, 10, 20-22, 27 AND 1, 11, 17, 25, 28 (IN PART)

Present claims 1, 11, 17, 28 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds as defined in claim 2, in claim 12 as well as in the description on p.6/1.7-20.

Present claims 3-8, 10, 20-22, 25, 27 relate to a composition/compounds defined by reference to a desirable characteristic or property, namely "amount equivalent to", "less than 90 wt%...", "no more than 60 minutes before or after...", "less than 60wt%.....", "exceeds the amount of.....".

The claims cover all composition/compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compositions/compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the composition/compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the products/compounds as defined in claims 2, 9, 12, 13, 14, 15.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/NL 02/00394

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 3-8, 10, 20-22, 27 AND 1, 11, 17, 25, 28 (IN PART)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

...formation on patent family members

International Application No

PCT/NL 02/00394

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
JP 10265397	A	06-10-1998	NONE	
JP 11001431	A	06-01-1999	NONE	
GB 1311015	A	21-03-1973	BE 758122 A1 CA 923425 A1 DE 2052131 A1 FR 2070174 A5 IE 34648 B1 IL 35477 A NL 7015348 A ZA 7006931 A	28-04-1971 27-03-1973 06-05-1971 10-09-1971 09-07-1975 29-08-1973 04-05-1971 28-07-1971
WO 0000188	A	06-01-2000	NO 982818 A AU 5536899 A CN 1309559 T EP 1007027 A2 WO 0000188 A2	15-03-2000 17-01-2000 22-08-2001 14-06-2000 06-01-2000
US 6004610	A	21-12-1999	NONE	
CN 1146867	A	09-04-1997	NONE	
EP 0477161	A	25-03-1992	AT 109955 T DE 59102557 D1 EP 0477161 A1	15-09-1994 22-09-1994 25-03-1992
EP 0856259	A	05-08-1998	EP 0856259 A1 AT 169456 T BR 9706278 A CA 2213113 A1 CN 1185904 A DE 69600525 D1 DE 69600525 T2 JP 10286078 A US 5895648 A	05-08-1998 15-08-1998 01-06-1999 23-06-1998 01-07-1998 15-10-1998 10-12-1998 27-10-1998 20-04-1999
WO 0133975	A	17-05-2001	NL 1013175 C2 AU 7971700 A EP 1217902 A1 WO 0133975 A1	30-03-2001 06-06-2001 03-07-2002 17-05-2001
WO 0033854	A	15-06-2000	NL 1010770 C2 AU 1896600 A EP 1137424 A1 WO 0033854 A1	13-06-2000 26-06-2000 04-10-2001 15-06-2000

THIS PAGE BLANK (USPTO)